Research shows that nasogastric tubes (feeding tubes through the nose) help esophageal cancer patients start treatment 21 days faster and cost half as much as surgical feeding tubes, while producing similar nutrition and allowing 68% of patients to eat normally again after treatment. According to Gram Research analysis of a 98-patient study, the simpler nose tube method appears equally effective without requiring surgery.
When people have advanced esophageal cancer that makes swallowing difficult, they need a way to get nutrition while undergoing cancer treatment. Researchers compared two methods: a thin feeding tube passed through the nose (nasogastric tube) versus a surgically created feeding opening in the stomach (enterostomy). According to Gram Research analysis, the nose tube got patients to cancer treatment 20 days faster, cost about half as much, and patients were more likely to eat normally again after treatment. Both methods provided similar nutrition during treatment, suggesting the simpler nose tube might be the better choice, especially in hospitals with limited resources.
Key Statistics
A 2026 cohort study of 98 esophageal cancer patients found that nasogastric tube feeding reduced time to cancer treatment start by 21 days compared to surgical feeding tubes (16 days vs. 37 days).
Nasogastric tube feeding cost approximately $11,194 per patient compared to $28,250 for surgical feeding tubes in a 2026 study of 98 esophageal cancer patients—a 60% cost reduction.
In a 2026 study of 98 esophageal cancer patients, 68% of those using nasogastric tubes resumed normal eating after treatment, compared to only 16% of surgical feeding tube patients.
A 2026 cohort study of 98 esophageal cancer patients showed nasogastric tube patients had hospital stays averaging 2.3 days versus 5.9 days for surgical feeding tube patients.
The Quick Take
- What they studied: Whether a feeding tube inserted through the nose or a surgically created feeding opening works better for esophageal cancer patients who can’t swallow during cancer treatment
- Who participated: 98 patients with advanced esophageal cancer that blocked their ability to swallow. Most patients (78) received the nose tube, while 19 had surgery. Researchers matched patients based on cancer stage and body weight to make fair comparisons.
- Key finding: Patients with nose tubes started cancer treatment 20 days faster (16 days vs. 37 days), paid about half as much for the feeding method ($11,194 vs. $28,250), and were more likely to eat normally again after treatment (68% vs. 16%). Both groups got similar nutrition during treatment.
- What it means for you: If you or a loved one faces this situation, the nose tube appears to be a simpler, faster, and cheaper option that works just as well. However, this study was done at one hospital in Thailand, so results may differ in other settings. Talk with your doctor about which option fits your specific situation.
The Research Details
Researchers looked back at medical records from 98 patients treated at King Chulalongkorn Memorial Hospital who had severe esophageal cancer blocking their ability to swallow. They compared patients who received a nasogastric tube (a thin plastic tube inserted through the nose into the stomach) with patients who had surgery to create a feeding opening directly into the stomach.
To make the comparison fair, researchers used a statistical technique called propensity score matching. This means they grouped patients with similar cancer stages and body weights together, so differences in results would come from the feeding method itself, not from patients being different to begin with. This approach helps reduce bias that can happen when comparing groups that weren’t randomly assigned to treatments.
The researchers measured several important outcomes: how long patients waited before starting cancer treatment, how much the feeding method cost, how long they stayed in the hospital, whether they experienced complications, and whether they could eat normally again after treatment finished.
This comparison matters because esophageal cancer patients need nutrition support during chemotherapy and radiation, but the method chosen affects how quickly they can start life-saving treatment. In hospitals with limited budgets and resources, choosing the most efficient method could help more patients get treated faster. The study design using propensity score matching strengthens the findings by reducing bias that often occurs in retrospective studies.
This study has some important strengths and limitations to understand. The main strength is that researchers used propensity score matching to create fair comparison groups, which is more rigorous than simply comparing all patients. However, the study looked backward at existing medical records rather than randomly assigning patients to treatments, which can introduce bias. The sample size of 98 patients is relatively small, and all patients came from one hospital in Thailand, so results may not apply everywhere. The study was published in a peer-reviewed surgical journal, indicating it met professional standards for quality.
What the Results Show
Patients who received nasogastric tubes (nose tubes) started their cancer treatment significantly faster than those who had surgery. On average, nose tube patients began treatment in 16 days compared to 37 days for surgery patients—a difference of 21 days. This faster start to treatment is important because every day matters when fighting cancer.
The cost difference was dramatic. The nose tube method cost about $11,194 per patient, while surgical feeding cost about $28,250—more than double the price. Hospital stays were also shorter for nose tube patients, averaging 2.3 days compared to 5.9 days for surgery patients.
One of the most encouraging findings was that patients who received nose tubes were much more likely to return to eating normally after their cancer treatment ended. About 68% of nose tube patients could eat regular food again, compared to only 16% of surgery patients. This suggests the nose tube doesn’t cause lasting damage to swallowing ability.
Nutrition levels during treatment were similar between both groups. Both groups lost weight and showed declining nutritional markers during cancer treatment, which is common. However, both groups recovered their nutrition within three months after finishing treatment, showing that the feeding method didn’t permanently harm their nutritional status.
Both groups experienced similar nutritional decline during active cancer treatment, which is expected because chemotherapy and radiation affect the whole body. The important difference was recovery: both groups bounced back nutritionally after treatment ended, suggesting neither feeding method caused lasting nutritional damage. The fact that nose tube patients were more likely to eat normally afterward suggests this method may be gentler on the swallowing mechanism long-term.
Previous research has suggested that surgical feeding tubes provide stable, long-term nutrition support, but this study challenges the idea that surgery is always necessary for cancer patients. The findings align with growing evidence that simpler, less invasive methods can work just as well when patients will receive treatment for a limited time. This study adds important cost and speed data that weren’t well-documented in earlier research.
This study has several important limitations. First, it’s relatively small with only 98 patients, so the findings might not apply to larger populations. Second, all patients came from one hospital in Thailand, so results may differ in other countries with different healthcare systems and resources. Third, the study looked backward at existing medical records rather than randomly assigning patients to treatments, which can introduce bias even with propensity score matching. Fourth, the study didn’t follow patients for a long time after treatment ended, so we don’t know about very long-term outcomes. Finally, the group receiving surgery was much smaller (19 patients) than the nose tube group (78 patients), which can affect statistical reliability.
The Bottom Line
For patients with advanced esophageal cancer who can’t swallow and need nutrition during cancer treatment, nasogastric tubes (nose tubes) appear to be a reasonable first choice. They get patients to treatment faster, cost significantly less, and allow more patients to eat normally again afterward. However, some patients may still need surgery if the nose tube doesn’t work or causes problems. Confidence in this recommendation is moderate because the study was done at one hospital and had a small sample size. Always discuss options with your cancer treatment team.
This research matters most for: patients with advanced esophageal cancer facing treatment decisions, cancer doctors and surgeons deciding on feeding methods, hospitals trying to manage costs while maintaining quality care, and healthcare systems in resource-limited settings. It may be less relevant for patients with different types of cancer or different medical situations. People without esophageal cancer or those with early-stage cancer that doesn’t affect swallowing don’t need to apply these findings.
Patients using nose tubes started cancer treatment about 3 weeks faster than surgery patients. During the 6-8 weeks of typical cancer treatment, both groups experienced nutrition decline. Recovery of normal eating ability and nutrition levels took about 3 months after treatment ended. Long-term outcomes beyond 3 months weren’t measured in this study.
Frequently Asked Questions
Is a feeding tube through the nose better than surgery for esophageal cancer patients?
For patients needing temporary nutrition support during cancer treatment, nasogastric tubes appear superior: they’re faster (21 days quicker to start treatment), cheaper (60% less cost), and allow more patients to eat normally afterward (68% vs. 16%). However, individual cases vary, so discuss with your doctor.
How long does it take to start cancer treatment with a nasogastric tube?
According to a 2026 study of 98 patients, those using nasogastric tubes started cancer treatment in an average of 16 days, compared to 37 days for surgical feeding tubes—a difference of about three weeks.
Can you eat normally again after using a feeding tube during cancer treatment?
Yes, most patients recover eating ability. A 2026 study found 68% of nasogastric tube patients resumed normal eating after treatment, compared to 16% of surgical tube patients. Both groups recovered nutrition levels within three months of finishing treatment.
How much does a nasogastric feeding tube cost compared to surgery?
Nasogastric tubes cost approximately $11,194 per patient versus $28,250 for surgical feeding tubes in a 2026 study—meaning the nose tube method costs about 60% less while producing similar nutritional outcomes.
Do both feeding methods provide the same nutrition during cancer treatment?
Yes, a 2026 study of 98 patients found comparable nutritional outcomes between nasogastric and surgical feeding tubes during cancer treatment. Both groups experienced similar weight loss during treatment and similar recovery within three months afterward.
Want to Apply This Research?
- If using a feeding tube during cancer treatment, track daily tube tolerance (comfort level 1-10), any feeding-related symptoms, and weekly body weight. This creates a record to share with your medical team and helps identify problems early.
- Users can set daily reminders for tube care and feeding schedules, log any discomfort or complications immediately, and track when they first tolerate small amounts of regular food again. This engagement helps patients stay involved in their recovery.
- Create a long-term tracking system that monitors: ability to eat regular foods (percentage of meals), body weight trends, energy levels, and any swallowing difficulties. Compare these metrics at treatment start, end, and 3 months post-treatment to measure recovery progress.
This research compares feeding methods for esophageal cancer patients and should not be used for self-diagnosis or self-treatment. The study was conducted at one hospital in Thailand and may not apply to all healthcare settings or populations. Feeding tube decisions should always be made in consultation with your oncologist, surgeon, and medical team who understand your specific medical situation. This article summarizes research findings and does not constitute medical advice. If you have esophageal cancer or swallowing difficulties, seek immediate care from qualified healthcare professionals.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
